Description：Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid.
It is a manufactured form of human insulin; where a single amino acid has been exchanged.
This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream.
As a result, it starts working in minutes, which allows one to take insulin and eat right away.
Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus.
It is a recombinant, biosynthetic, fast-acting insulin analogue.
Compared to human insulin, it has a single amino acid substitution at position B28 where proline is replaced with aspartic acid.
This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin.
Principle of the assay： The method employs the qualitative enzyme immunoassay technique.
A commercially available Aspart is pre-coated onto microwells.
Samples and Controls are pipetted into microwells and antibodies to human Aspart present in the sample and controls are bound by Aspart.
In the second step, a HRP （horseradish peroxidase） conjugate is pipetted and incubated.
Excess HRP conjugate will be removed by washing.
Addition of TMB substrate will develop blue color and intensity of blue colour in wells are proportional to the concentration of anti- Aspart antibody present in Positive control or sample.
Color development is then stopped by addition of stop solution.
